|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that SLC22A18 may act as a tumor suppressor by regulating the expression levels of cell growth-related proteins, and vinca alkaloids might show therapeutic efficacy against low-SLC22A18-expressing breast cancer.
|
30145211 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate CLImAT-HET's ability to accurately recover clonal compositions using tumor WGS data without a match normal sample.
|
28298214 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the 60 SDHD tumours investigated, four tumours showing retention of chromosome 11 showed SLC22A18 and CDKN1C expression levels comparable to levels in tumours showing loss of chromosome 11, suggesting loss of protein expression despite chromosomal retention.Our data strongly suggest that SLC22A18 and/or CDKN1C are tumour modifier genes involved in the tumourigenesis of SDHD-linked paraganglioma.
|
27402879 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, these findings offer the convincing evidence that the roles of SLC22A18 in NSCLC progression may be partially caused by the regulatory effects of miR-137, which may function as a tumor suppressor.
|
25498886 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we established SLC22A18 as a tumor suppressor in colon epithelial cells and propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.
|
26196590 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of SLC22A18 on the in vivo tumor radiosensitivity was investigated in the orthotopic mice model.
|
24481489 |
2014 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
SLC22A18 promoter methylation and protein expression were examined by methylation-specific polymerase chain reaction (MSP) and Western blotting respectively, then we compared SLC22A18 promoter methylation and protein expression in tumor cell explants in regard to prediction of TMZ response and survival time of 86 GBM patients.
|
23514245 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SLC22A18 [solute carrier family 22 (organic cation transporter) member 18] is located within the 11p15.5 cluster, and may be a new tumor suppressor gene; evidence of SLC22A18 hypermethylation is documented in several types of human cancers.
|
21993522 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.
|
21936894 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC22A18 expression was correlated with tumor size, lymph node metastasis, clinical stage, and extensive lyphovascular invasion.
|
21144813 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TSSC5 (tumor-suppressing subchromosomal transferable fragment cDNA; also known as ORCTL2/IMPT1/BWR1A/SLC22A1L) is located in the region.
|
16314844 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BWR1A mRNA expression was determined in 14 HBs by differential RT-PCR of matched cDNA samples from tumor and normal liver.
|
15239143 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical analysis showed that high HET/SAF-B expression in these tumors was associated with low S-phase fraction and with aneuploidy, consistent with our results from transfection experiments in tissue culture cells.
|
10999774 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reverse transcription-PCR analysis of TSSC5 revealed frequent occurrence of aberrant RNA splicing, which deleted exons 4, 5, and 6 in Wilms' tumors.
|
9751628 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although SSCP analysis of 62 WT samples and 10 BWS patients did not result in the identification of any mutations in ORCTL2 or ORCTL2S, it will be important to examine their expression pattern in tumors and BWS patients, since epigenetic alteration at these loci may play a role in the etiology of these diseases.
|
9570947 |
1998 |